Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 11,377 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Leigh Syndrome
Interventions
None (Observational study)
Other
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Non-small Cell Lung Cancer
Interventions
ISIS EIF4E Rx, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more
Conditions
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
Interventions
L-Bcl-2 antisense oligonucleotide
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more
Conditions
Colorectal Cancer
Interventions
fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Boston, Massachusetts
Completed Phase 2Phase 3 Interventional Results available

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232
Conditions
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
Isoquercetin
Drug
Lead sponsor
Jeffrey Zwicker, MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Conditions
Central Nervous System Neoplasms, Central Nervous System Tumor
Interventions
Tc-99m tilmanocept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Necrotizing Enterocolitis, Bronchopulmonary Dysplasia, Growth Failure
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 33 Weeks
Enrollment
300 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Sacramento, California
Not listed No phase listed Observational

Pancreatic Cancer Biomarker Study

NCT04143152
Conditions
Pancreatic Adenocarcinoma
Interventions
Not listed
Lead sponsor
Van Andel Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
GastroEsophageal Cancer
Interventions
Immune checkpoint inhibitor (ICI) or chemotherapy alone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
APG-1387 for Injection
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas
Completed No phase listed Observational Results available

Laser Ablation After Stereotactic Radiosurgery

NCT01651078
Conditions
Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
Interventions
Not listed
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
New Haven, Connecticut • Kansas City, Kansas • St Louis, Missouri + 4 more
Conditions
Gastroparesis, Lung Transplant; Complications
Interventions
High Resolution Electrogastography
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Completed No phase listed Observational Accepts healthy volunteers Results available

Follow-Up Extension to the Family Study of Binge Eating Disorder

NCT00777634
Conditions
Binge Eating Disorder
Interventions
No intervention.
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Residual Neuromuscular Blockade
Interventions
Standardized NMBD Management
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Uveitis
Interventions
Ustekinumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Chandler, Arizona • Long Beach, California • Redlands, California + 16 more
Conditions
Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
ALXN1830
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Healthy Volunteers
Interventions
There is no intervention
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional

Novel Imaging Markers in SPMS

NCT05357833
Conditions
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Interventions
Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Interventions
Investigational medical product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 1 more